Bracco Diagnostics, subsidiary of contrast developer Bracco Imaging, has received U.S. Food and Drug Administration (FDA) approval for the use of its Varibar barium contrast agent in modified barium swallow studies.
Specifically, Varibar thin liquid (barium sulfate) is now indicated with modified barium swallow examinations to evaluate the oral and pharyngeal functions and morphology in adult and pediatric patients, according to the vendor. Modified barium swallow studies are performed to detect and assess the severity of dysphagia on fluoroscopy.
